Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Arrowhead Research Corporation
Arrowhead Nanobiotechnology Subsidiaries, Calando Pharmaceuticals and Insert Therapeutics, Complete Merger
May 9th, 2008
Arrowhead Research Corporation (Nasdaq:ARWR) announced the completion of the merger between Insert Therapeutics, Inc. and Calando Pharmaceuticals, Inc. The merger is part of a streamlining of the two companies in which Arrowhead assumed active management to increase efficiency and focus resources on bringing multiple products to the clinic as rapidly as possible. The merged company will do business under the name "Calando Pharmaceuticals, Inc." "Both Calando and Insert are on track to maximize value from their core technologies and each has recently announced progress toward additional clinical trials," said Christopher Anzalone, Arrowhead's CEO. "The companies are...
Source: Health Business Week (2008-05-09)
|
